Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Gemphire Therapeutics Announces Pricing of Initial Public Offering

Tuesday, August 09, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

NORTHVILLE, Mich. -- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease) today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on August 5, 2016 under the ticker symbol "GEMP".  The offering is expected to close on August 10, 2016, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock.


Jefferies LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.  Canaccord Genuity Inc. is acting as co-lead manager for the offering and Laidlaw & Company (UK) Ltd. and LifeSci Capital LLC are acting as co-managers.


Read full article.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by®  ::  Legal